Awards
2024
In-house developed product Yallaferon® was honoured with “2024 Most Valuable Product in Partnership for Drug Store Chain in China” Award by Menet
Honoured with “2023 Top 100 Chinese Chemical Pharmaceutical Companies” by Menet
Azilsartan Tablets won the “Guangdong Prominent High-tech Products” award
2023
Honoured with the “Best Pharmaceutical Company of The Year Award” by BIOHK2023
Honoured with the 1st “Most Popular (ESG) Enterprise Award in the GBA”
In-house developed product Yallaferon® was honoured with “2023 Most Valuable Product in Partnership for Drug Store Chain in China” Award by Menet
Honoured with “2022 Top 100 Chinese Chemical Pharmaceutical Companies” by Menet
Sodium Phenylbutyrate Granules won the “Guangdong Famous High-tech Products” award
Guangzhou Zhaoke Lian Fa Pharmaceutical Limited was honoured with “Excellence Enterprise Award of Gold Pilot Award 2022”
Development of Antiplatelet Thrombolysin was honoured with “Second Prize of the 8th Hefei City Industrial Achievements in Technology and Innovation”
2022
Honoured with “Most Valuable Companies in Hong Kong 2022 Awards – Most Innovative Pharmaceutical Company” by Mediazone Group
In-licensed product Ferplex® was honoured with “2022 Most Valuable Product in Partnership for Drug Store Chain in China” Award by Menet
Honoured with “2021 Top 100 Chinese Chemical Pharmaceutical Companies” by Menet
Zhaoke Pharmaceutical (Hefei) Company Limited was honoured with the award of “2021 Anhui Provincial Role Model Enterprise in Consumer Products Industry”
2021
In-house product Yallaferon® was honoured with “2021 Biopharmaceutical Excellent Brand” Award
Honoured with “2020 Top 100 Chinese Chemical Pharmaceutical Companies” by Menet
2019
Honoured with “Most Innovative Small and Medium-sized Pharmaceutical Enterprises Award in the Asia Pacific Region 2019” by Clarivate Analytics
Honoured with “Most Growing Award” at “China Enterprise Excellence Awards Ceremony 2019”
Honoured with “2019 China 2nd Future Unicorn Competition Top 10 in China”
2018
Honoured with “The Top 50 of Innovative Biotechnology Enterprises in Guangdong-Hong Kong-Macau Greater Bay Area”
Dr. Benjamin Li was honoured with “The 16th World Outstanding Chinese Award” by World Chinese Business Investment Foundation
2017
Honoured with “Best Listed Companies Category 2017” by Forbes
2016
Honoured with “Intellectual Technology Award” and “Recognition of Enterprise Award”
2015
Listed as “Top 42 Innovative Enterprise” in China
Honoured with “Asia’s 200 Best Under a Billion” 2015 by Forbes
Dr. Benjamin Li was honoured with “EY Entrepreneur of The Year 2015 China” by EY
Zhaoke Pharmaceutical (Hefei) Company Limited Ranked Second in 2014 for “the Number of Declared New Drug Application”
2013
Honoured with “Asia’s 200 Best Under a Billion” 2013 by Forbes
2012
Honoured with “Technology Achievement Award 2012” by Hong Kong Awards for Industries
Honoured with “Asia’s 200 Best Under a Billion” 2012 by Forbes
2011
Honoured with “Asia’s 200 Best Under a Billion” 2011 by Forbes
Honoured with “500 Best in Asia Pacific 2011” by Deloitte
2010
Honoured with “500 Best in Asia Pacific 2010” by Deloitte
Honoured with “Hong Kong Outstanding Enterprises 2010” by Economic Digest
Accredited “Asia’s Best Companies 2010 (China) Best Small Cap” ranked 2nd
2009
Honoured with the “Double Excellent Enterprise” by Chinese Government
